FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
12 letters match. Newest first.
-
DrugsAmgen Inc.
FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.
Medium -
DrugsImmunityBio, Inc.
FDA says ImmunityBio's Anktiva TV ad and podcast falsely claim it can cure or prevent all cancers.
High risk -
DrugsHims & Hers Health, Inc. dba Hers
FDA warned Hims & Hers (Hers) that its website misleads consumers about compounded semaglutide by implying it is the same as approved Ozempic and Wegovy.
Medium -
DrugsSlendid
FDA warned Slendid that its website sells compounded semaglutide and tirzepatide with a false "clinically proven" claim, making the drugs misbranded.
Medium -
DrugsTRYM Health, Inc. dba TRYM Health
FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.
Medium -
DrugsEli Lilly and Company
FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.
High risk -
DrugsSprout Pharmaceuticals, Inc.
FDA warned Sprout Pharmaceuticals that a CEO Instagram post for Addyi omitted risks and indication limits.
High risk -
DrugsSarfez Pharmaceuticals, Inc.
FDA says Sarfez made false or misleading efficacy and risk claims for Soaanz (torsemide) in webpages, pamphlet, and exhibit panel.
High risk -
DrugsAstraZeneca Pharmaceuticals LP
FDA says AstraZeneca's Breztri sales aid made false or misleading efficacy claims, making the COPD drug misbranded.
Low -
DrugsCytoDyn, Inc.
FDA warns CytoDyn over video promoting unapproved leronlimab as safe and effective for COVID-19.
High risk -
DrugsCooperSurgical, Inc.
FDA says CooperSurgical’s Paragard video omitted all risk information, making the birth-control promotion misleading and misbranded.
Low -
DrugsAcelRx Pharmaceuticals, Inc.
FDA says AcelRx's DSUVIA banner and display ads misbrand the opioid tablet by oversimplifying dosing and understating risks.
High risk